For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder.
Mitomycin is activated in vivo to a bifunctional and trifunctional alkylating agent. Binding to DNA leads to cross-linking and inhibition of DNA synthesis and function. Mitomycin is cell cycle phase-nonspecific.
Oral, mouse: LD<sub>50</sub> = 23 mg/kg; Oral, rat: LD<sub>50</sub> = 30 mg/kg. Symptoms of overdose include nausea and vomiting.
Erratic.
8-48 min
Approximately 10% of a dose of mitomycin is excreted unchanged in the urine.